Olivier Martinon, DVM, MS is the Vice President of External Innovation & Research Alliances for Zoetis. He has a passion for innovation coupled with deep roots in veterinary sciences across the development of recombinant and vectored vaccines as well as monoclonal antibodies. Since joining Zoetis, formally, Pfizer Animal Health, in 2006, Olivier has held a variety of roles. He most recently led the development of Librela, approved in Europe as the first monoclonal antibody to alleviate osteoarthritis in dogs. He managed the entire biotherapeutic portfolio from 2007 to 2020 including mAbs, proteins and peptides in his role as First Biopharma Council Chairman. Prior to joining Zoetis, Olivier worked on the development of recombinant and live vector vaccines at Merial in both France and the United States. He received his DVM from École Nationale Vétérinaire d'Alfort and DEA/MS degree from Pierre and Marie Curie Paris VI University. He trained in Molecular Biology with CIRAD working on eradication programs of cattle paramyxoviruses in Africa.